预约演示
South Korean biotech group spies US SPAC as route to Nasdaq
2023-07-12
并购IPO
The plan is to take the holding company onto the Nasdaq under the new name OSR Biosciences in the fourth quarter.
OSR Holdings is the latest biotech business to choose a merger with a speciOSR Biosciencesisition company (SPAC) as a way to hop onto the public markets.
OSR Holdings Korea-headquartered OSR is a global healthcare holding company with operations including a pair of subsidiaries in South Korea and Switzerland focused on developing drugs for oncology and osteoarthritis. The company also owns a distributor of medical devices for neurovascular and other diseases and last week announced plans to acquire Landmark BioVentures, another Swiss company that operates four oncology- and immunology-focused biotech ventures in France.
The latest announcement will see OSR merge with U.S.-based Bellevue Life Sciences Acquisition. The SPAC went public in February with a $60 million IPO and the goal of finding a suitable heoncology-focuosteoarthritis join forces with. In OSR, it appears to have found the desired target, and the plan is to take the holding company onto the Nasdaq undLandmark BioVenturesBiosciences in the fourth quarter of the year.
The only clinical-stage candidateOSR OSR’s portfolio is VXM01, an immunotherapy in phase 1/2 development by the Swiss-German biotech Vaximm for glioblastoma in combination with Merck KGaA’s Bavencio. Vaximm also has therapies targeting tOSRproteins mesothelin, WT1 and PD-L1 in preclinical development.OSR Biosciences
"We are delighted to identify OSR Holdings as our candidVXM01 Bellevue Life Sciences Acquisition's CEO Kuk Hyoun Hwang said in a postmarket releglioblastomay. “OSR Holdings reprMerck KGaAimely investment opportunity working on the development of bremesothelinthWT1pies PD-L1nmet medical needs."
While SPAC deals were a hot tiOSR Holdingstechs to go public a couple of years ago, the rush cooled in 2022 as the industry hit tough times. Since then, their uOSR Holdingsmore sporadic, with some companies testing the SPAC waters again near the year’s end. This spring also saw a trickle of merger announcements, with Anew Medical, enGene and NKGen Biotech all opting for the blank check route to market.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。